Haploidentical Stem Cell Transplant for Blood Cancers

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

Recruiting Phase 1 Interventional Study
Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Hodgkin Lymphoma Non-Hodgkin Lymphoma Myelodysplastic Syndrome Myeloproliferative Syndrome Rhabdomyosarcoma Ewing Sarcoma Primitive Neuroectodermal Tumor Osteosarcoma Neuroblastoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
7 Months – 21
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
22 (estimated)
Sponsor
University of Wisconsin, Madison · Other
Who this trial is looking for

This trial is looking for children with certain types of blood cancers or solid tumors who have not responded to standard treatments. Participants will receive a stem cell transplant from a matched donor along with a special drug called Zoledronate after the transplant.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have a hematologic malignancy or solid tumor.
  • I have an eligible haploidentical donor.
  • I have had a relapse or my cancer has not responded to previous treatments.
  • I have been off prior cancer treatment for at least three months.
  • I can expect to live for at least three more months.
  • I have a performance score of 60 or higher.
  • My kidney function is normal.
  • I am willing to sign consent or have a guardian do so.

You may not be able to join if

  • I am pregnant or breastfeeding.
  • I am infected with HIV.
  • I have uncontrolled heart problems.
  • I have a serious active infection.
  • I have had a significant illness unrelated to cancer.
  • I am involved in another clinical trial.
  • I have had an organ transplant.
  • I have severe central nervous system issues.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant period to treat pediatric patients with relapsed or refractory hematologic malignancies or high risk solid tumors.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Availability of an eligible haploidentical donor * Hematologic malignancy or solid tumor * Patients with more than one malignancy (hematologic or solid tumor) are eligible * Patients with hematologic malignancy must have no HLA identical sibling or suitable unrelated donor OR …
Contacts

Jenny Weiland

608-890-8070

PedsHemOncResearch@g-groups.wisc.edu

CONTACT

Celeste Matsushima

608-890-8069

CONTACT